Aziende Chimiche Riunite Angelini Francesco S.p.a
Clinical trials sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.a, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cenobamate tested in real life for stubborn seizures Results expected Mar 2027 (estimated)
-
New hope for epilepsy: Real-World data on Cenobamate's impact
Disease control OngoingThis study looks at how well the drug cenobamate works for adults with focal seizures that don't improve with at least two other epilepsy medicines. Researchers are collecting data from Italian clinics and a compassionate use program to measure seizure reduction and side effects.…
Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A • Aim: Disease control
Last updated Jun 26, 2026 15:21 UTC
-
Real-World epilepsy study tracks Add-On drug effectiveness
Knowledge-focused OngoingThis study follows 300 adults with focal epilepsy who are starting an additional anti-seizure medication (ASM) alongside their current treatment. Researchers will track changes in seizure frequency and quality of life over 12 months in everyday clinical settings. The goal is to s…
Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:45 UTC